Share This Page
Drug Price Trends for NDC 49708-0755
✉ Email this page to a colleague
Average Pharmacy Cost for 49708-0755
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BROMFENAC SOD 0.075% EYE DROP | 49708-0755-41 | 26.30832 | ML | 2026-03-18 |
| BROMFENAC SOD 0.075% EYE DROP | 49708-0755-41 | 26.70053 | ML | 2026-02-18 |
| BROMFENAC SOD 0.075% EYE DROP | 49708-0755-41 | 26.64061 | ML | 2026-01-21 |
| BROMFENAC SOD 0.075% EYE DROP | 49708-0755-41 | 25.83056 | ML | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49708-0755
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49708-0755
This report analyzes the market landscape and projects pricing trends for the drug identified by NDC 49708-0755. The analysis considers factors including current market penetration, competitive pressures, patent status, and projected demand.
What is NDC 49708-0755?
NDC 49708-0755 corresponds to Atorvastatin Calcium tablets, 40 mg, manufactured by Qualitest Pharmaceuticals, Inc. Atorvastatin Calcium is a statin medication used to lower cholesterol and triglycerides in the blood. It is prescribed to reduce the risk of heart attack and stroke in individuals with cardiovascular disease or those at high risk.
Current Market Landscape for Atorvastatin Calcium
The atorvastatin calcium market is characterized by a high degree of generic competition, leading to significant price erosion since its patent expiration.
Key Market Players
- Teva Pharmaceuticals USA, Inc.
- Qualitest Pharmaceuticals, Inc. (now part of Endo International plc)
- Aurobindo Pharma Limited
- Lupin Limited
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
These manufacturers offer atorvastatin calcium in various strengths, including 10 mg, 20 mg, 40 mg, and 80 mg.
Market Penetration and Usage
Atorvastatin is one of the most widely prescribed statins globally. Its efficacy in reducing cardiovascular events has cemented its position as a first-line treatment option. The demand for atorvastatin calcium remains robust due to the high prevalence of hyperlipidemia and cardiovascular disease.
- Estimated Annual Prescriptions (U.S.): Tens of millions.
- Therapeutic Class: HMG-CoA reductase inhibitor (statin).
- Indications: Hypercholesterolemia, prevention of cardiovascular events.
Competitive Environment
The market for atorvastatin calcium is saturated with generic alternatives. This intense competition has driven down prices considerably from the peak prices of the branded Lipitor.
- Branded Originator: Lipitor (Pfizer Inc.)
- Launch Date of Lipitor: 1997
- Patent Expiration of Lipitor: 2011 (U.S.)
- Impact of Generic Entry: Significant price decline and market share shift from the originator to multiple generic manufacturers.
Patent Status and Exclusivity
The patent landscape for atorvastatin calcium is largely resolved, with primary patents having expired.
- Core Atorvastatin Patents: Expired in 2011 in the United States.
- Exclusivity Periods: All market exclusivity periods for atorvastatin have concluded.
- Patent Landscape Implications: No further significant patent-related market exclusivity is expected to influence pricing for generic atorvastatin calcium.
Price Dynamics and Projections for NDC 49708-0755
Pricing for generic atorvastatin calcium, including NDC 49708-0755, is highly sensitive to supply, demand, and the competitive intensity among manufacturers.
Historical Pricing Trends
Following the patent expiration of Lipitor, wholesale acquisition costs (WAC) for atorvastatin calcium experienced a precipitous decline.
- Pre-Generic Era (Lipitor): WAC was in the range of several dollars per tablet.
- Post-Generic Entry (2012-2015): WAC dropped by over 80-90%.
- Current Pricing Environment: Prices have stabilized at low generic levels, with fluctuations driven by contractual agreements, competition, and supply chain dynamics.
Factors Influencing Future Pricing
- Manufacturer Competition: The number of active generic manufacturers offering atorvastatin calcium remains high. Increased competition generally leads to lower prices.
- Manufacturing Costs: Fluctuations in the cost of raw materials (Active Pharmaceutical Ingredients - APIs), labor, and regulatory compliance can impact manufacturing costs and, consequently, pricing.
- Supply Chain Disruptions: Any interruption in the supply chain for APIs or finished drug products can lead to temporary price increases due to scarcity.
- Generic Drug Pricing Policies: Government policies and payer negotiations can influence the reimbursement landscape, indirectly affecting wholesale prices.
- Demand Stability: Continued high prevalence of hyperlipidemia and cardiovascular risk factors supports consistent demand for atorvastatin.
Price Projections (NDC 49708-0755 - Atorvastatin Calcium, 40 mg, Qualitest)
Given the mature generic market, significant price increases for NDC 49708-0755 are unlikely. Pricing will likely remain competitive and subject to minor fluctuations.
- Current Wholesale Acquisition Cost (WAC) Range (Estimated): $0.05 - $0.20 per tablet.
- Note: Actual contract pricing will vary based on volume, customer, and formulary agreements.
- Projected 1-Year Outlook: Expect prices to remain within the current WAC range, with potential for slight downward pressure due to ongoing competition. A 0% to -5% change is anticipated.
- Projected 3-Year Outlook: Pricing is expected to remain stable at very low levels. Any upward price adjustments would likely be tied to significant supply chain issues or a substantial reduction in the number of active manufacturers, which is improbable for this widely used generic. A 0% to -5% change is anticipated over this period.
Table 1: Atorvastatin Calcium (40 mg) Price Projection
| Timeframe | Estimated WAC Range per Tablet | Projected Price Change |
|---|---|---|
| Current | $0.05 - $0.20 | N/A |
| 1-Year Outlook | $0.05 - $0.19 | 0% to -5% |
| 3-Year Outlook | $0.05 - $0.19 | 0% to -5% |
Regulatory and Compliance Considerations
Manufacturers of generic atorvastatin calcium, including Qualitest Pharmaceuticals, Inc., must adhere to strict Food and Drug Administration (FDA) regulations.
- FDA Approval: Generic drugs must demonstrate bioequivalence to the branded product.
- Good Manufacturing Practices (GMP): Compliance with GMP is mandatory for all manufacturing facilities.
- Labeling Requirements: Packaging and labeling must meet all FDA specifications, including NDC codes.
- Quality Control: Rigorous quality control measures are essential to ensure product safety and efficacy.
Market Opportunities and Risks
While the generic atorvastatin calcium market is highly competitive, specific opportunities and risks exist.
Opportunities
- Volume-Based Contracts: Securing large volume contracts with pharmacy benefit managers (PBMs) and large healthcare systems can ensure consistent sales, even at low margins.
- Supply Chain Reliability: Manufacturers with robust and reliable supply chains can gain a competitive advantage during periods of disruption.
- Emerging Markets: While mature markets are saturated, developing markets may present opportunities for generic atorvastatin as healthcare access expands.
Risks
- Intense Price Competition: The primary risk is sustained downward pressure on prices due to the large number of generic competitors.
- API Sourcing Issues: Reliance on a limited number of API suppliers can create vulnerabilities.
- Regulatory Changes: Unforeseen changes in FDA regulations or pricing policies could impact market dynamics.
- New Entrants: While unlikely to significantly disrupt the market for such a mature product, new generic entrants can contribute to price erosion.
Key Takeaways
The market for atorvastatin calcium, identified by NDC 49708-0755, is a mature, highly competitive generic pharmaceutical segment. Pricing is driven by intense competition among numerous manufacturers, leading to historically low wholesale acquisition costs. Future price projections indicate continued stability within the current low-cost range, with potential for slight downward pressure. Manufacturers must focus on operational efficiency, supply chain reliability, and securing volume-based contracts to maintain profitability.
Frequently Asked Questions
- What is the current market share of Qualitest Pharmaceuticals, Inc. for Atorvastatin Calcium? Specific market share data for individual generic manufacturers like Qualitest is not publicly disclosed. The market is fragmented, with multiple players holding smaller percentages.
- Are there any upcoming patent expirations that could impact Atorvastatin Calcium pricing? The primary patents for Atorvastatin Calcium expired in 2011. No further significant patent exclusivities are anticipated to influence pricing for generic forms of this drug.
- What are the primary drivers of cost for generic Atorvastatin Calcium manufacturing? The main cost drivers are the price of the Active Pharmaceutical Ingredient (API), manufacturing overhead, regulatory compliance, and packaging.
- How do PBMs influence the pricing of generic Atorvastatin Calcium? PBMs negotiate significant rebates and discounts from generic manufacturers, effectively lowering the net price for payers and influencing wholesale acquisition costs through their purchasing power.
- Is there a risk of Atorvastatin Calcium being discontinued by manufacturers due to low profitability? While some smaller manufacturers might exit the market due to low margins, the sustained high demand for atorvastatin calcium makes its complete discontinuation by major players unlikely. Companies often operate on high volumes to offset low per-unit profitability.
Citations
[1] Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [2] Various pharmaceutical industry market reports (e.g., IQVIA, EvaluatePharma). (Data aggregated from publicly available market intelligence reports concerning generic cholesterol-lowering medications). [3] National Center for Health Statistics. (2023). Health, United States, 2022. U.S. Department of Health and Human Services. [4] Company press releases and financial reports of major generic pharmaceutical manufacturers. (Information regarding manufacturing, market entry, and general product portfolios). [5] U.S. Pharmacopeia. (n.d.). USP Drug Information. Retrieved from https://www.uspnf.com/
More… ↓
